$3
Allogene Therapeutics is a biotechnology business based in the US. Allogene Therapeutics shares (ALLO) are listed on the NASDAQ and all prices are listed in US Dollars. Allogene Therapeutics employs 232 staff and has a trailing 12-month revenue of around $87,000.
Our top picks for where to buy Allogene Therapeutics stock
How to buy Allogene Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ALLO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Allogene Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Allogene Therapeutics stock price (NASDAQ: ALLO)
Use our graph to track the performance of ALLO stocks over time.Allogene Therapeutics shares at a glance
Latest market close | $2.91 |
---|---|
52-week range | $2.01 - $5.78 |
50-day moving average | $2.57 |
200-day moving average | $3.26 |
Wall St. target price | $11.51 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.78 |
Is it a good time to buy Allogene Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Allogene Therapeutics price performance over time
Historical closes compared with the close of $2.91 from 2024-07-25
1 week (2024-07-19) | 2.83% |
---|---|
1 month (2024-06-27) | 19.26% |
3 months (2024-04-26) | 0.69% |
6 months (2024-01-26) | -10.19% |
1 year (2023-07-27) | -38.48% |
---|---|
2 years (2022-07-27) | -79.21% |
3 years (2021-07-27) | 21.61 |
5 years (2019-07-26) | 29.36 |
Allogene Therapeutics financials
Revenue TTM | $87,000 |
---|---|
Gross profit TTM | $243,000 |
Return on assets TTM | -26.71% |
Return on equity TTM | -55.48% |
Profit margin | 0% |
Book value | $2.71 |
Market Capitalization | $590.9 million |
TTM: trailing 12 months
Allogene Therapeutics share dividends
We're not expecting Allogene Therapeutics to pay a dividend over the next 12 months.
Allogene Therapeutics share price volatility
Over the last 12 months, Allogene Therapeutics's shares have ranged in value from as little as $2.01 up to $5.775. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allogene Therapeutics's is 0.851. This would suggest that Allogene Therapeutics's shares are less volatile than average (for this exchange).
Allogene Therapeutics overview
Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18. 2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.
Frequently asked questions
nullWhat percentage of Allogene Therapeutics is owned by insiders or institutions?
Currently 17.54% of Allogene Therapeutics shares are held by insiders and 64.469% by institutions. How many people work for Allogene Therapeutics?
Latest data suggests 232 work at Allogene Therapeutics. When does the fiscal year end for Allogene Therapeutics?
Allogene Therapeutics's fiscal year ends in December. Where is Allogene Therapeutics based?
Allogene Therapeutics's address is: 210 East Grand Avenue, South San Francisco, CA, United States, 94080 What is Allogene Therapeutics's ISIN number?
Allogene Therapeutics's international securities identification number is: US0197701065 What is Allogene Therapeutics's CUSIP number?
Allogene Therapeutics's Committee on Uniform Securities Identification Procedures number is: 019770106
More guides on Finder
-
How to invest in ARK Venture Fund (ARKVX)
Learn how to invest in Cathie Wood’s ARK Venture Fund in 5 easy steps.
-
Best brokerage accounts for index funds [July 2024]
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
-
Options trading strategies for beginners
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
Ask a question